Supplements and Featured Publications
- Real-World Insights on Biomarker Testing Patterns and Implications for mNSCLC Therapy Selection
Participating Faculty: Real-World Insights on Biomarker Testing Patterns and Implications for mNSCLC Therapy Selection
Faculty
Amy Stanford, PharmD
Director
Value Strategy & Evidence, US Market Access
AstraZeneca
Wilmington, DE
Shawn Boykin, PhD
Senior Director
Value Strategy & Evidence, US Market Access
AstraZeneca
Wilmington, DE
Karishma Desai, PhD, MS, BPharm
Associate Director
HEOR
Carelon Research
Wilmington, DE
Pritesh S. Karia, PhD, MPH
Associate Director
Oncology Outcomes Research
AstraZeneca
Gaithersburg, MD
Kim C. Ohaegbulam, MD, PhD
Resident Physician
Department of Radiation Medicine
Oregon Health & Science University
Portland, OR
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Amy Stanford, PharmD
EMPLOYMENT
AstraZeneca
STOCK OWNERSHIP
AstraZeneca
Shawn Boykin, PhD
EMPLOYMENT
AstraZeneca
STOCK OWNERSHIP
AstraZeneca
Pritesh S. Karia, PhD, MPH
EMPLOYMENT
AstraZeneca
STOCK OWNERSHIP
AstraZeneca
Karishma Desai, PhD, MS, BPharm, and Kim C. Ohaegbulam, MD, PhD, have no relevant commercial financial relationships or affiliations to disclose.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
